Medical device programs
Development, manufacturing, and sales of medical device programs
First generation
Medical device programs that have an “affinity” with current cognitive tests
The product under development traces the similar task concepts for evaluation (i.e., memory, attention/judgment, composition, and language functions) of conventional cognitive assessment tools, including the MMSE and Hasegawa dementia scale. Conserving a sort of familiarity with the current methods, the new system will feature an evaluation that is low stress, simple, objective, and quantitative.
Our first-batch product of MIREVO® verified a positively high correlation in total score between this application and MMSE. With those validated efficacy, this device has obtained the regulatory approval of medical device from the MHLW Japan.
The ETCA system uses images combined with simple tasks and thus easily supports multiple languages. We will expand the market overseas, focusing on the Asian region where a significant increase in the number of patients with dementia is predicted.
Our first-batch product of MIREVO® verified a positively high correlation in total score between this application and MMSE. With those validated efficacy, this device has obtained the regulatory approval of medical device from the MHLW Japan.
The ETCA system uses images combined with simple tasks and thus easily supports multiple languages. We will expand the market overseas, focusing on the Asian region where a significant increase in the number of patients with dementia is predicted.
Second generation
Next-generation devices leveraging Artificial Intelligence (AI) technology
We proceed with the development of next-generation technology that includes the analysis of the gaze plot recorded during the cognitive test. This addition of the “time” element in analysis and the diagnosis algorithm supported by AI and machine learning produce highly accurate and effective information for the differential diagnosis of dementia.
There are several types of dementia, such as Alzheimer’s disease and dementia with Lewy bodies; each has a different causative disease.
Naturally, treatment is different for respective cases. Therefore, differentiation is considered of utmost importance in the clinical settings.
We believe the eye tracking-based cognitive assessment (ETCA) system can provide a solution. By accumulating continuous gaze plot data, and if diseases showing particular eye movements / visual functions can be identified by AI analysis, we can develop a type of next-generation dementia diagnosis support equipment that is useful for differentiation.
The differential diagnosis of dementia, which so far relies on highly specialized knowledge and the expertise of doctors, is expected to be performed more simply and objectively, and patients with dementia can receive more appropriate treatment and care.
There are several types of dementia, such as Alzheimer’s disease and dementia with Lewy bodies; each has a different causative disease.
Naturally, treatment is different for respective cases. Therefore, differentiation is considered of utmost importance in the clinical settings.
We believe the eye tracking-based cognitive assessment (ETCA) system can provide a solution. By accumulating continuous gaze plot data, and if diseases showing particular eye movements / visual functions can be identified by AI analysis, we can develop a type of next-generation dementia diagnosis support equipment that is useful for differentiation.
The differential diagnosis of dementia, which so far relies on highly specialized knowledge and the expertise of doctors, is expected to be performed more simply and objectively, and patients with dementia can receive more appropriate treatment and care.